ACROBIOSYSTEMS CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.98 CNY | +1.51% |
|
-7.77% | -30.47% |
| Apr. 24 | Acrobiosystems Co.,Ltd. Proposes Final Cash Dividend for 2023 | CI |
| Apr. 18 | Acrobiosystems Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 16,890 | 8,215 | 7,071 | 4,906 | - | - |
| Enterprise Value (EV) 1 | 16,890 | 8,215 | 7,071 | 4,906 | 4,906 | 4,906 |
| P/E ratio | 76.8 x | 60.5 x | 46 x | 28.2 x | 18.9 x | 18.4 x |
| Yield | 0.71% | 1.46% | 1.53% | 1.73% | 2.19% | 4.1% |
| Capitalization / Revenue | 43.9 x | 17.3 x | 13 x | 7.61 x | 5.97 x | 5.18 x |
| EV / Revenue | 43.9 x | 17.3 x | 13 x | 7.61 x | 5.97 x | 5.18 x |
| EV / EBITDA | 81.1 x | 34 x | 35.3 x | 25.5 x | 17.7 x | 18.1 x |
| EV / FCF | - | - | -404 x | 42.3 x | 29.4 x | 22.7 x |
| FCF Yield | - | - | -0.25% | 2.36% | 3.4% | 4.4% |
| Price to Book | 6.85 x | 3.21 x | 2.73 x | 1.83 x | 1.69 x | 1.66 x |
| Nbr of stocks (in thousands) | 120,000 | 120,000 | 119,970 | 119,726 | - | - |
| Reference price 2 | 140.8 | 68.46 | 58.94 | 40.98 | 40.98 | 40.98 |
| Announcement Date | 4/14/22 | 4/25/23 | 4/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 385 | 474.4 | 543.7 | 644.5 | 822.3 | 947.6 |
| EBITDA 1 | - | 208.2 | 241.7 | 200.1 | 192.4 | 277 | 271.8 |
| EBIT 1 | - | 195.6 | 216.5 | 161.1 | 188 | 259.8 | 285.5 |
| Operating Margin | - | 50.82% | 45.62% | 29.63% | 29.18% | 31.59% | 30.13% |
| Earnings before Tax (EBT) 1 | - | 195.4 | 215 | 160.7 | 187.5 | 259.3 | 285 |
| Net income 1 | 115.9 | 174.2 | 203.7 | 153.6 | 174.6 | 259.9 | 267.2 |
| Net margin | - | 45.25% | 42.94% | 28.25% | 27.1% | 31.61% | 28.2% |
| EPS 2 | 1.287 | 1.834 | 1.132 | 1.280 | 1.455 | 2.165 | 2.228 |
| Free Cash Flow 1 | - | - | - | -17.49 | 116 | 167 | 216 |
| FCF margin | - | - | - | -3.22% | 18% | 20.31% | 22.8% |
| FCF Conversion (EBITDA) | - | - | - | - | 60.31% | 60.3% | 79.47% |
| FCF Conversion (Net income) | - | - | - | - | 66.43% | 64.25% | 80.84% |
| Dividend per Share 2 | - | 1.000 | 1.000 | 0.9000 | 0.7100 | 0.8967 | 1.680 |
| Announcement Date | 4/8/21 | 4/14/22 | 4/25/23 | 4/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 |
|---|---|
| Net sales 1 | 146 |
| EBITDA | - |
| EBIT | - |
| Operating Margin | - |
| Earnings before Tax (EBT) | - |
| Net income 1 | 30.67 |
| Net margin | 21.01% |
| EPS | - |
| Dividend per Share | - |
| Announcement Date | 4/23/24 |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -17.5 | 116 | 167 | 216 |
| ROE (net income / shareholders' equity) | - | 27.4% | 8.13% | 5.98% | 6.46% | 8.71% | 8.95% |
| ROA (Net income/ Total Assets) | - | 6.85% | 7.72% | - | 6% | 7.15% | 8.4% |
| Assets 1 | - | 2,545 | 2,640 | - | 2,910 | 3,635 | 3,181 |
| Book Value Per Share 2 | - | 20.60 | 21.40 | 21.60 | 22.40 | 24.30 | 24.70 |
| Cash Flow per Share 2 | - | 1.150 | 1.680 | 0.9300 | 1.280 | 1.550 | 2.110 |
| Capex 1 | - | 61.7 | 284 | 129 | 82 | 65.5 | 85.1 |
| Capex / Sales | - | 16.01% | 59.85% | 23.67% | 12.73% | 7.96% | 8.98% |
| Announcement Date | 4/8/21 | 4/14/22 | 4/25/23 | 4/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
40.98
CNY
Average target price
60.89
CNY
Spread / Average Target
+48.59%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -30.47% | 669M | |
| +32.09% | 694B | |
| +29.39% | 593B | |
| -1.34% | 371B | |
| +20.34% | 331B | |
| +7.39% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +8.49% | 169B |
- Stock Market
- Equities
- 301080 Stock
- Financials Acrobiosystems Co.,Ltd.
